ALBANY, N.Y. (AP) — Critics are throwing shade at Gov. Andrew Cuomo's pricey plan to install high-tech, color-changing lights on New York City's bridges, questioning whether the investment is the best use of public money.A government watchdog group this month called for a state probe into what it says are conflicting explanations for how much the lights cost and where that money will come from.De Blasio, who has frequently sparred with his fellow Democrat, urged Cuomo to reallocate the money for emergency repairs on the subway system, which has been plagued by mounting delays, derailments and other problems caused by decades of neglect.Despite initial reports that the Metropolitan Transportation Authority would foot the bill, the state now says the money will come from economic development funds and proceeds from the state's Power Authority, which often works on big energy efficiency projects.
NYS Entity Status
NYS Filing Date
AUGUST 21, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - DE DEVELOPMENT GROUP INC
Around the Web
- Critics throw shade at Cuomo's plan to light NYC bridges
By DAVID KLEPPER, Associated Press - Sunday Aug 13, 2017
- IAB Tech Lab Launches Blockchain Working Group
Monday Sep 18, 2017
GroupM, Kochava, MetaX, and Nyiax have become member companies in an IAB Tech Lab working group that launched Monday focused on blockchain and explore ways to use it in digital technology. ShailleySingh leads the group. The working group will initially design ways to educate the industry, set priorities for business use cases and develop standards and best practices.
- Insurance Giant Aetna Is Leaving Hartford for New York City
By SARAH MASLIN NIR - Thursday Jun 29, 2017
Aetna will move to new headquarters in Manhattan, drawn by New York’s emergence as a digital powerhouse, as well as financial incentives.
- Solar Developers and Panel Makers Clash Over Tariff Request
By DIANE CARDWELL - Tuesday Aug 15, 2017
Troubled domestic manufacturers say cheap Chinese products have undercut their own, but industry groups are urging a trade panel to reject sanctions.
- Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
By Caroline Chen - Tuesday Oct 17, 2017
Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]